ReachMD CME
ReachMD
Recent Episodes
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/patient-case-tailoring-first-line-treatment-for-a-patient-with-metastatic-melanoma-and-impaired-performance-status/24368/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/what-dermatologists-surgeons-need-to-know-adjuvant-treatment-for-resectable-stage-iiiiv-melanoma/24380/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-immunotherapy-related-adverse-events-during-adjuvant-treatment-for-resectable-melanoma/24382/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/case-consult-adjuvant-therapy-following-localized-treatment-for-stage-iii-melanoma/24381/
This educational initiative will enhance dermatologists' and surgeons' knowledge, clinical skills, and confidence in recognizing patients who may benefit from adjuvant systemic therapy and selecting individualized, appropriate agents to improve outcomes for patients with stage IIB-IV resectable melanoma.
Valid until: 26-04-2025
Claim your CME credit at https://reachmd.com/programs/cme/future-directions-targeting-lag-3-in-melanoma-treatment/24369/
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.